The first fully integrated, tubeless wearable with dual-hormone closed-loop control. Insulin pump, glucagon pump, and CGM in one device — designed to improve outcomes and reduce patient burden.
Designed to address the key limitations of current insulin pump therapy.
Integrated glucagon automatically rescues from severe lows before they become emergencies. Designed to dramatically reduce nocturnal hypoglycemia events.
Dual-hormone closed-loop control targets optimal glucose range. The algorithm adjusts both insulin and glucagon to minimize glycemic variability.
By continuously optimizing glucose levels through automated dual-hormone delivery, Pancreum is designed to help patients achieve tighter control with less effort.
With on-board glucagon rescue, severe hypoglycemia events that currently require emergency intervention could be prevented at the device level.
How Pancreum advances beyond today's pump therapy options.
| Capability | Pancreum | Current Pumps |
|---|---|---|
| Insulin delivery | Automated closed-loop | Hybrid closed-loop (manual bolus) |
| Glucagon delivery | Integrated, automatic | Separate emergency kit |
| CGM | Built into the wearable | Separate device + transmitter |
| Nocturnal safety | Dual-hormone protection | Insulin-only suspend |
| Patient burden | Single device, smartphone control | Multiple devices, manual management |
| Form factor | Tubeless, integrated wearable | Varies; most have tubing |
The current smartphone-controlled platform is the foundation. Our roadmap leads to a fully AI-controlled system that learns each patient's unique patterns and manages their diabetes autonomously — reducing clinician and patient burden alike.
510(k)
FDA clearance pathway
Benchtop
Testing methodology
4 Patents
Issued + 1 pending
We are seeking clinical partners and advisory board members in endocrinology. If you are interested in collaborating, we would love to connect.